Share your clinical perspective and help shape future understanding of neurological care.
Ambit is conducting a market research advisory board with physicians to better understand how clinicians interpret emerging clinical data, evaluate treatment options, and make real-world decisions for patients with developmental and epileptic encephalopathies (DEE), including SCN2A and SCN8A.
We are inviting a small group of qualified physicians to participate in a moderated, in-person discussion alongside peers.
A single, full-day engagement — no follow-ups, no homework. Designed to fit within a Saturday or a focused weekday.
A professional facilitator guides the conversation; practicing physicians provide the perspective.
Structured stimulus materials, anonymized cases, and recent literature.
Scheduled May–June. Choose the city and date most convenient for you.
Fair-market value compensation aligned with Sunshine Act reporting requirements.
Airfare, ground transportation, and hotel arranged and reimbursed per policy.
A short screener confirms eligibility in about 3–5 minutes.
Not intended to influence clinical practice. Your participation is for research insight only.
Individual responses are kept confidential and are reported only in aggregated, anonymized form.
The sponsor's identity will be shared with qualified participants after the eligibility screener is reviewed.
Participation is subject to eligibility criteria and applicable Sunshine Act reporting requirements.
Please complete the short screener below. It will take approximately three to five minutes.
